Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of both early and advanced cutaneous T-cell lymphoma (CTCL). Although bexarotene has been used for decades in the treatment of CTCL, little is known about the mechanisms underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanita, Kayo, Fujimura, Taku, Sato, Yota, Lyu, Chunbing, Kambayashi, Yumi, Ogata, Dai, Fukushima, Satoshi, Miyashita, Azusa, Nakajima, Hideki, Nakamura, Motoki, Morita, Akimichi, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763730/
https://www.ncbi.nlm.nih.gov/pubmed/31616630
http://dx.doi.org/10.3389/fonc.2019.00907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763730/
https://www.ncbi.nlm.nih.gov/pubmed/31616630
http://dx.doi.org/10.3389/fonc.2019.00907

Ejemplares similares